October 2023 Update

Serving the NC Life Sciences Industry

ncbioscience.net

919.281.8960

The passage of the budget means that Medicaid will expand in North Carolina. Medicaid expansion extends health care coverage to more than 600,000 North Carolinians and, the expansion will go into effect Dec. 1.

 

The budget includes a 7% raise for state employees and teachers over the next two years. School bus drivers will get an additional 2% raise, bringing their raise to 9%. Most State Highway Patrol officers will also get higher raises, at about 11%.

 

Overall, a number of NCLifeSci's priorities fared well in the budget.

• Innovation funding: The legislature focused its start-up funding priorities on authorizing and funding NCInnovation, which received $250 million in each year of the biennium, along with another $250 million in a funding reserve. The NCInnovation Board may invest the state money and use the interest gained for various research commercialization purposes.  
• The One NC Small Business Program did not receive additional funding beyond its $2 million recurring appropriation.
• Water/wastewater grants: The legislature appropriated $2 billion dollars in water, wastewater and sewer infrastructure grants, designating more than 200 specific and mostly rural high priority projects.
• Franchise tax: The budget caps the franchise tax beginning in 2025 and rates will change starting in 2024. The budget sets a minimum tax for all corporations at $200 and a maximum of $150,000. C corporations will pay a flat fee of $500 for the first $1 million of their tax base and an additional $1.50 for every $1,000 that exceeds $1 million. S corporations will pay $200 for the first $1 million of their tax base and $1.50 for every $1,000 of the excess amount.
• NCBiotech: The NC BIotechnology Center received a recurring increase of $1 million with a nonrecurring appropriation of an additional $2 million during the first year of the biennium.

Other tax changes include a schedule that could drop the personal income tax as low as 2.49% if certain revenue triggers are hit each year.

 

The budget was delayed for weeks as the chambers debated the authorization of rural entertainment districts that would have allowed gaming and casinos. The regulation of video lottery terminals was also part of the debate. Ultimately, neither gaming proposal moved forward, clearing the way for budget passage, including an earlier stipulation that the expansion of the Medicaid population in North Carolina would take effect along with the budget.

 

Some less usual provisions in the budget include funding for voter ID implementation, a prohibition on local governments setting minimum wage standards and raising lobbyist registration fees from $250 to $500 a year. The budget expands powers for the Joint Legislative Commission on Government Operations, known as Gov Ops, and exempts state legislators from state public records law. 

Doug Edgeton, NCBiotech

Dan Jenkins, Pairwise

Sen. Mike Woodard and Rep. Donna White, co-chairs of the Life Sciences Caucus

The NC General Assembly's Life Sciences Caucus met Monday, Sept. 18, at the Plant Sciences Building on the North Carolina State University Centennial Campus..

 

Members of BIO's Agriculture and the Environment Team were on hand to give an overview of both federal issues and state issues affecting the agbio and environmental industries.

• Federal issues discussed included the U.S.-Mexico trade dispute over an upcoming import ban on genetically engineered corn, recent U.S. EPA plant incorporated protectants regulation and the Plant Biostimulants Act in the delayed Farm Bill.
• Issues moving in states throughout the country include legislation banning or restricting vaccination of livestock, incentivizing sustainable aviation fuel production and use and bills banning or restricting foreign ownership of agricultural land, which can adversely impact R&D.

Pairwise, which has a new produce product on the market, talked about EPA impediments to their business. Representatives from BASF, Hoofprint Biome, Novozymes and Syngenta were also available.

 

Celeste Brogdon, director of strategic engagement for the NC Plant Sciences Initiative, gave an overview of the initiative and then attendees took a tour of the building.

There were three redistricting committee meetings held across the state last week to allow for public comment on the issue of redrawing maps for both the NC legislature and Congressional seats. 

 

Meetings were held in Elizabeth City, Hickory and Raleigh. Sen. Ralph Hise (R-Mitchell), one of the chairs of the redistricting committee, confirmed that Wednesday’s hearing was the last before votes on new maps begin. Senate leader Phil Berger has said that votes on a new redistricting plan could begin by the week of Oct. 9.

If there are any topics or issues that are affecting your business

or you want to know more about, please contact Laura Gunter.

The Senate approved a stopgap funding bill Saturday night, and President Joe Biden signed it just in time to avert a government shutdown.

 

The legislation effectively pushes the deadline for a new 2024 appropriations bill to Nov. 17. It passed the Senate 88-9. The package was approved by the House 335-91, with all but 90 Republicans and almost all Democrats supporting it.

 

The continuing resolution drops aid to Ukraine, provides $16 billion in supplemental funding for disaster relief and includes temporary extensions for the following expiring health care programs:

• Extends the animal drug and generic drug user fee agreements through FY2028
• Funds community health centers, the National Health Service Corps, Teaching Health Center Graduation Medical Education and Special Diabetes Programs through Nov. 17
• Extends key disaster and medical response authorities through Nov. 17
• Delays Medicaid Disproportionate Share Hospital cuts for hospitals through Nov. 17
• Extends child and family service welfare programs, Sexual Risk Avoidance Education and the Personal Responsibility Education through Nov. 17

Health care extenders are fully offset by reducing the funds in the Medicaid Improvement Fund by $642 million.

 

Congress let key health programs expire, including the SUPPORT Act tackling the opioid epidemic, the U.S. President's Emergency Plan for AIDS Relief known as PEPFAR and the Pandemic and All-Hazards Preparedness Act. It’s unclear what the immediate practical consequences will be.

Rep. Wiley Nickel (D-NC) and Rep. John Joyce, M.D. (R-PA) introduced the Optimizing Research Progress Hope And New Cures Act, a welcome and bipartisan fix to the Inflation Reduction Act’s negative impact on the development of drugs to treat rare diseases, according to BIO President and CEO Rachel King.  

 

The IRA exempts orphan drugs for rare diseases from price negotiations but only if the drugs are approved for a single indication. Drug manufacturers are not encouraged to test whether a new drug can treat other indications.

 

"Encouraging R&D for drugs to treat rare diseases is difficult as is," King said. "By definition, orphan drugs benefit small patient populations, making investment in this space incredibly risky. But there is tremendous need for these treatments. Fewer than 5 percent of rare diseases have an FDA approved treatment.

 

"We have repeatedly warned that the IRA -- by subjecting drugs that can treat more than one rare disease to government price controls -- creates even more barriers to investment into follow-on research and development for orphan drugs."

 

The ORPHAN Cures Act changes the incentive structure within the IRA to encourage follow-on investment into orphan drug development. Reversing IRA’s perverse incentives will eliminate the significant barrier created that would prevent new waves of rare disease drug innovation. 

 

Nickel and staff representatives from the offices of Sen. Ted Budd; Rep. Gregory Murphy, M.D.; and Rep. Deborah Ross were part of an August roundtable convened by NCLifeSci and hosted by Alexandria Real Estate Equities to discuss barriers to innovation created by the IRA. The roundtable allowed several companies, including G1 Therapeutics, Mycovia Pharmaceuticals, Tavros Pharmaceuticals and Ribometrix, to weigh in on needed changes.

Novo Nordisk  AbbVie, Merck, AstraZeneca, Bristol-Myers Squibb and Boehringer Ingelheim have agreed to participate in Medicare drug price negotiations.

 

Several of the companies and industry trade groups have filed lawsuits seeking to overturn the policy mandated by the Inflation Reduction Act. The U.S. Chamber of Commerce, one of the groups challenging the Biden administration’s implementation of the negotiations, had asked a federal judge in Ohio for a preliminary injunction to halt the negotiation process, but the judge declined to do so. The judge also refused the Justice Department's request to dismiss certain suits.

 

Drugmakers had until Oct. 1 to agree to Medicare price talks and then submit data to CMS on the selected drugs. The agency will examine the data and come up with an initial offer of a price for each product by Feb. 1. The companies can either accept the price or enter a series of talks going through Aug. 1. CMS will publish a final price on Sept. 1, and that price will go into effect on Jan. 1, 2026.

A bill designed to prevent pharmacy benefit managers from using their market power to drive up drug prices was introduced in the Senate Sept. 28.

 

The Modernizing and Ensuring PBM Accountability Act, introduced by Senate Finance Committee Chair Ron Wyden (D-OR) and Ranking Member Mike Crapo (R-I), is designed to make PBM practices more transparent and to increase competition in the pharmaceutical supply chain.

 

PBMs choose which drugs receive insurance coverage, charging drug makers rebates and fees for covering them. PBMs profit from keeping drug prices high and are often integrated with pharmacy chains and insurers with three PBMs controlling 80% of the market.

 

The bill would prevent PBMs from taking Medicare compensation based on “sticker prices,” establish independent audit and enforcement measures to increase transparency and give relief to independent pharmacies, which face uncompetitive pressure from PBMs.

The Food and Drug Administration on Sept. 29 proposed eventually subjecting most laboratory-developed tests to stricter review as medical devices. This is a multiyear phaseout of discretionary enforcement that the agency said is necessary to ensure the tests' accuracy and to save the health care system billions of dollars a year.

 

Laboratory-developed tests are created and used within a single laboratory and are designed for a wide range of diseases. The FDA is concerned that its decades-long practice of not enforcing certain regulatory requirements for LDTs has led to a situation in which tests don't perform as well as diagnostic tests that undergo strict FDA review.

 

The FDA's proposed rule would phase out its discretionary enforcement of certain regulatory requirements for LDTs over a period of several years. During this time, the FDA would work with industry to develop a new regulatory framework for LDTs.

 

The American Clinical Laboratory Association, which represents clinical laboratories, said the proposed rule "exceeds FDA's existing authority" and that LDTs are not medical devices. The ACLA also expressed concern that the proposed rule could reduce access to testing, undermine innovation and increase health care costs.

 

The FDA estimates that the proposed rule would reduce health care system costs more than $22.3 billion per year and cost industry and the FDA $5.6 billion per year. The agency is taking comments on the proposed rule for 60 days.

The Advanced Research Projects Agency for Health announced the launch of ARPANET-H, a nationwide health innovation network anchored by three ARPA-H regional hubs. The hubs will be mission-focused, regional centers with a growing network of spokes from around the country representing the diversity of people, settings and capabilities that encompass the American health ecosystem.

 

The three hubs of ARPANET-H will lead specific focus areas, including streamlining customer experiences, catalyzing investors, and developing stakeholder and operations efforts.

• The Customer Experience hub will focus on developing health solutions that will be accessible, needed, and readily adopted. It will take a proactive approach to diversify clinical trials, reach representative patient populations, and more leading to better and more equitable health outcomes for all. This hub’s physical location will be located in Dallas.
• The Investor Catalyst hub will focus on speeding the transition of innovative ideas into practical, accessible solutions that deliver for Americans by engaging with researchers, entrepreneurs, and investors. This hub’s physical will be located in Cambridge, Mass., in the greater Boston area.
• The Stakeholder and Operations hub will be adjacent to many intergovernmental partners and stakeholders. Following a competitive review, ARPA-H will select the final site located in the National Capital Region, using federal leasing and acquisition procedures. The announcement is anticipated later in 2023.

Together, the hubs and spokes will collaborate with ARPA-H to catalyze game-changing breakthroughs in science and medicine that improve health outcomes. ARPANET-H will enable health problems to be solved faster, with accessible, equitable solutions reaching the American public more quickly. The network advances President Biden’s Unity Agenda by driving innovation of new ways to prevent, detect, and treat for cancer, Alzheimer’s, diabetes, and other diseases. More at ARPA-H

The Institute for Clinical Economic Review on Monday released a new methodology for assessing the value of treatments, but it still uses a measure considered discriminatory.

 

ICER is a nonprofit offering cost analyses of new treatments that has been criticized by BIO and others for ignoring patient and societal values. Payers and pharmacy benefit managers use ICER in determining insurance coverage for prescription drugs, affecting patient access. In 2018, 78% of payers said ICER recommendations influenced drug coverage decisions, a study found.

 

ICER’s first update to its Value Assessment Framework in three years includes some improvements, like more patient engagement and methodology to rate clinical trials based on overall demographic diversity, but it still used quality-adjusted life years, a calculation of a treatment’s benefit that considers a year of perfect health superior to a year of living with illness.

 

QALYs discriminate against people with disabilities and chronic conditions, according to the National Council on Disability, BIO and patient groups. 

 

ICER’s update ignores calls for improvements, such as adding additional dimensions of value and a proposed Generalized Risk-Adjusted Cost-Effectiveness Analysis, which would give a more holistic assessment of effects on patients, caregivers and society.

Bill Monteith

William “Bill” Monteith has been selected by the NC Life Sciences Organization as the new program director for the organization’s Biomanufacturers Forum.

 

Over the course of his 42-year career, Monteith has overseen the construction of and served as site head of at least six solid dose and biotech facilities. He succeeds John Wagner, who directed the forum for eight years before retiring in June. 

 

Monteith recently retired as chief operating officer of Stride Bio and, prior to that, he served as executive vice president technical operations and sr. vice president U.S. manufacturing for Cellectis, chief operating officer of Hitachi Chemical Advanced Therapeutic Solutions and executive vice president technical operations for Dendreon. He has also held leadership positions in operations and manufacturing, MSAT/technical services and quality operations at Wyeth and Shire.

Pfizer Inc. has restarted the majority of its manufacturing lines at its Rocky Mount facility following severe damage from the tornado that hit the site on July 19. 

 

The resumption of production also includes the launch of one line in the site’s new sterile injectable manufacturing area referred to as R3, a state-of the-art module approved earlier this year by the FDA. This expedited restart is only the first step toward full recovery for the plant as Pfizer restarts production through a phased approach with full production across the site’s three manufacturing suites anticipated by the end of 2023, the company said. 

 

Production restart has been prioritized based on patient need and inventory levels, Pfizer said. There are approximately 13 medicines in production on the lines that have restarted, including products that are currently available through Pfizer’s emergency ordering process. The first shipments of these medicines to distribution centers are anticipated in the fourth quarter of 2023. The effects of the tornado on the site are expected to affect the supply of medicines from the Rocky Mount facility until at least mid-2024. More >>

North Carolina Agricultural and Technical State University was granted $5.8 million by the National Institutes of Health to create a genomics educational hub that will provide new educational and research opportunities for undergraduate and master’s students who are historically underrepresented in biomedical sciences.

 

The Genomics Research and Data Science Center for Computation and Cloud Computing will use cloud computing platforms to share educational resources for genomic data science to ensure its accessibility to various institutions who may not have sophisticated computing facilities.

 

GRADS-4C will be based at A&T and will anchor a community of institutions, including Shaw University, Winston-Salem State University and North Carolina Central University, that are serving students from diverse backgrounds, including those from groups historically underrepresented in biomedical sciences, and are invested in genomic data science education. The hub will facilitate educational and research initiatives at these institutions through workshops and hands-on learning sessions while developing strategies to address their educational and training challenges in underserved communities. More >>

Josh Jones of Frankel Staffing, Ellen King of Novozymes and Jamie Ousterout of The Diversity Movement were the panelist for a Sept. 12 online discussion of the "Rising and Failing of Employee-Led Groups." You can watch the recording on our YouTube channel.

The Diversity Movement can provide you with the resources to accelerate your DEI initiatives with excellence. Here are some of their latest updates. 

 

TDM products have expanded from MicroVideos, digital courses and DEI Navigator to TDM Library. TDM products are designed to help organizations excel in their DEI education without financial barriers presenting a challenge. 

 

TDM is launching a 45-day trial access to its DEI Navigator on Oct. 1. The company aims to help small businesses and organizations win at DEI by resourcing their leaders to transform the workplace. 

BioAgilytix and Sweden's A3P Biomedical AB have entered a partnership to introduce Stockholm3, as a lab developed test designed to redefine the standard of care for early detection of prostate cancer in the U.S. More >>

 

BioAgilytix was named to the Triangle Business Journal's Fast 50 recognizing the 50 fastest growing private companies in the region. More >>

 

Biocair won Best Cell & Gene Therapy Supplier Award ? APAC and Best Cell & Gene Therapy Supplier Award ? Supply Chain Excellence at the Asia-Pacific Cell & Gene Therapy Excellence Awards Sept. 14 in Singapore. More >>

 

Biofidelity announced the U.S. commercial launch of ASPYRE-Lung, a novel assay that simplifies and accelerates the detection non-small cell lung cancer. More >>

 

Biogen Inc. completed the acquisition of Reata Pharmaceuticals, Inc., a company focused on therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. As a result, Biogen acquired SKYCLARYS (omaveloxolone) and other pipeline programs.

 

Biogen Inc. announced that the FDA has approved TOFIDENCE (tocilizumab-bavi) intravenous formulation for the treatment of moderately to severely active rheumatoid arthritis and juvenile idiopathic arthritis. More >>

 

Clancy & Theys Construction Co. was named to the Triangle Business Journal's Fast 50 recognizing the 50 fastest growing private companies in the region. More >>

 

Humacyte, Inc. announced positive top line results from its V005 Phase 2/3 trial of the Human Acellular Vessel in vascular trauma repair. Humacyte plans to file a Biologics License Application for the treatment of vascular trauma during the 4th quarter of 2023. More >>

 

IQVIA has appointed Richard Staub III, currently senior adviser to the chairman and CEO, as president of its Research & Development Solutions business unit. More >>

 

Kymanox was named to the Triangle Business Journal's Fast 50 recognizing the 50 fastest growing private companies in the region. More >>

 

Longfellow Real Estate Partners unveiled Via Labs at Hub RTP as the new name and brand of its life science development that is currently underway at the Hub RTP project in the Research Triangle. More >>

 

The NC Biotechnology Center will receive $10,000 from the SBA over two years as part of the AgTech Innovation Alliance to support and promote innovation in crop science, animal health, food tech and precision agriculture. More >>

 

PQE Group has established a new North American office in Montreal, the company's seventh office location in North America. More >>

 

SAS has been chosen by AstraZeneca to help increase efficiency and drive automation in the delivery of statistical analyses for clinical and postapproval submissions to regulatory authorities, via SAS’s cloud-based software and technologies. More >>

 

Syneos Health, Inc. announced the completion of its acquisition by a consortium of private investment firm affiliates composed of Elliott Investment Management L.P., Patient Square Capital and Veritas Capital. More >>

 

Syneos Health, Inc. has signed an agreement with Maha Chakri Sirindhorn Clinical Research Center of Chulalongkorn University that expands the company’s clinical trial capabilities in Thailand. More >>

 

TARGAN has officially opened its new facility called the Midtown BioCenter in Raleigh with Gov. Roy Cooper attending the Sept 12 event. More >>

Regarded as a homecoming for the global medtech community, this event serves as the incubator for the ideas, partnerships and innovations that lead to a healthier world.

 

The 2023 conference will take place in Anaheim, Californa, where you can engage in face-to-face conversations that will enhance your passion for what you do, enjoy quality programming focused on today’s hot topics and experience the best networking in the business. Tomorrow’s advancements start with us ? be part of the most prestigious gathering of medtech leaders.

 

Contact Amber Niebauer for a discount code for 10% off the registration fee.

There are many myths when it comes to breast cancer, such as that an annual mammogram will ensure early detection, but nearly 50% of all women have dense breasts (and many have no idea) and mammograms alone do not work on women with dense breasts at least 50% of the time. This is most concerning among women aged 30s-50s because that's when women have the highest breast density. By 60, the density decreases so mammograms work better. The challenge is the tumor is white and the breast tissue is white so it is like trying to find a snowball in a snowstorm. 

 

Learn more and dial in for life-saving myth-busting on Oct. 12. from 1-2 p.m.

Join Pfizer for an event intended to inspire best-in-class disability hiring initiatives: 

 

Oct. 25
9 a.m. to 12 p.m.

4300 Oak Park Rd
Sanford, NC 27330

 
Check-in is 8:30 a.m. to 9 a.m. The program will begin at 9 a.m., followed by networking, refreshments and site tours.

 

Pfizer is most excited to showcase its Learn to Work program, where they have partnered with Lee County Schools and the Office of Exceptional Children in an effort to provide professional work experiences for students with Intellectual and Developmental Disabilities.

 

Pfizer also plans to share the SourceAbled program, an enterprise program designed to deliver sustainable solutions for attracting, hiring, and retaining qualified talent who are autistic, neurodivergent or have disabilities.

 

Respond by Friday, Oct. 13, to nicole.griffin-gatchalian@pfizer.com if you would like to attend.

Join the Economic Development Partnership of North Carolina and its partners from US Commercial Services and the Small Business & Technology Development Center for a lunch and learn about the free services and grants available to help achieve new sales in international markets for both new-to-export and experienced companies.

 

The panel will also provide insight from North Carolina companies; National Drug Source, which has successfully used these resources and exports to dozens of countries; and Sciencix, which received the National Small Business Exporter of the Year Award by the Small Business Administration.

 

Panel

• Lisa Bamford, director of business development and global marketing, Sciencix (moderator)
• Emily Gereffi, senior international trade specialist, USCS
• Mike Hubbard, director of international trade, EDPNC
• Ethel Torres, president & CEO, National Drug Source
• Alex Viva, director of international business development and director of Capital Regional Center, SBTDC

This conference is a highly curated intentional space for innovative thinkers to come together to address some of the world's biggest health issues in an inclusive, creative, and bold environment. It will be a space for learning, sharing, reflecting, and connecting, and will serve as just the first step for countless conversations that we will bring forward into the coming year.

Save the date for a Pfizer Ignite event to be held at the NC Biotechnology Center Nov. 13. Hosted by NCLifeSci and NCBiotech.

Register today for MDMA's 2023 Reimbursement & Health Policy Conference being held in Washington, DC Nov. 8-9.  

 

MDMA is the leading voice for innovative and entrepreneurial medical device companies, and this year's Reimbursement & Health Policy Conference will deliver key insights on MedTech reimbursement and market access issues. 

• MDMA Members - $695
• State Members - $795
• Non-Members - $895 

Contact Amber Niebauer for a discount code worth $100 off the registration fee.

The High Flyer Awards Luncheon celebrates and honors those companies and individuals who have contributed to high science, high impact innovation and the entrepreneurial ecosystem as a whole.

 

Join First Flight Venture Center in celebration of the entrepreneurial spirit at our Third Annual High Flyer Awards Luncheon on Nov. 17 from 11 a.m. - 1 p.m. at Prestonwood Country Club.

For over two decades, the annual Genesis conference has brought key Life Science opinion leaders and stakeholders together to debate key trends, instigate deals and generate a vision of the future.

 

Genesis offers a high content mix of plenary talks and panels from key opinion leaders, 1-2-1 Partnering, an exhibition assembling an array of providers supporting the life science sector, ample networking opportunities and online Innovation Workshops.

 

NCLifeSci members can contact Amber Niebauer for a discount code worth 10% off the registration fee.

• Navigating the EU Medical Device Regulation (MDR) hosted by U.S. Department of Commerce (10/5/2023)
• Science of Socializing hosted by Azzur Group (10/5/2023)
• Particle Technology for Dry Powder Inhalers hosted by NCSU BMIG (10/6/2023)
• MedTech Conference hosted by AdvaMed (10/9/2023 to 10/11/2023)
• Hands-On Single-Use Processing for Biopharmaceuticals hosted by BTEC (10/10/2023 to 10/12/2023)
• Microbial Contamination Control in Bioprocessing Operations hosted by BTEC (10/10/2023 to 10/12/2023)
• International Life Sciences and Real Estate Conference hosted by BISNOW (10/11/2023 to 10/12/2023)
• Busting Breast Cancer Myths to Save Lives Congressional Briefing (10/12/2023)
• Brews + Bytes hosted by NC TECH (10/12/2023)
• Export Coffee Talk: STEP 11 Grant Offerings, Insights, and Inspiration hosted by EDPNC (10/13/2023)
• BIO Investor Forum (10/17/2023 to 10/18/2023)
• Black Women in Clinical Research Conference  (10/20/2023 to 10/22/2023)
• Upstream Production Process Development for Biopharmaceuticals hosted by BTEC (10/23/2023 to 11/3/2023)
• Applied Principles and Techniques of Depth Flow Filtration (DFF) and Tangential Flow Filtration (TFF) for BioPharm Downstream Purification hosted by BTEC (10/24/2023 to 10/27/2023)
• Export Education: Export 201 hosted by EDPNC (10/24/2023)
• HUB RTP Open House hosted by RTP (10/25/2023)
• International Trade Resources: Free Services & Grants hosted by EDPNC (10/26/2023)
• Resilience in the Global Health Ecosystem hosted by NC Global Health Alliance (11/1/2023)
• Reimbursement and Health Policy Conference hosted by MDMA (11/8/2023 to 11/9/2023)
• NCBIO Clinical Research Luncheon and Forum: Recruiting and Retaining Study Participants (11/8/2023)
• Carolina Startup Connect hosted by Innovate Carolina (11/8/2023 to 11/9/2023)
• CEO Center Program at MEDICA  (11/13/2023 to 11/16/2023)

PSC Software has redesigned its website to reflects the company’s commitment to staying at the forefront of technology and offering its users an immersive and user-friendly online experience. 

 

PSC’s Software solutions have accelerated clients success by enabling them to be more efficient, compliant and collaborative. PSC Software has solutions that support both large organizations along with start-up organizations, in the life sciences industry. 

 

The enhanced PSC Software website offers a seamless blend of modern design, user-friendly interfaces and comprehensive information. It is now easier than ever for users to maximize the value of PSC Software by exploring, sharing knowledge and building meaningful partnerships.

Save on the resources you need to heal, fuel, and feed the world. From lab products and office supplies to HR and regulatory consulting, BIO Business Solutions has you covered.

© Copyright 2023 North Carolina Life Sciences Organization